Clinical validation and utility of Percepta GSC for the evaluation of lung cancer

Keyphrases

• Lung Cancer 100%
• Clinical Utility 100%
• Clinical Validation 100%
• Genomic Sequencing Classifier 100%
• Percepta 100%
• Lung Lesions 60%
• Low Risk 40%
• Positive Predictive Value 40%
• Negative Predictive Value 40%
• Bronchoscopy 40%
• Invasive Procedures 40%
• Intermediate Risk 40%
• Risk Classification 40%
• High Risk 20%
• Risk of Malignancy 20%
• Nondiagnostic 20%
• Malignant Lesions 20%
• Benign Lesion 20%
• Malignancy 20%
• Predictive Value 20%
• Very Low Risk 20%
• Sensitivity Specificity 20%
• Ultra-high Risk 20%
• Highly Accurate 20%
• Bronchial Epithelium 20%
• Improved Management 20%
• Bronchial Brushing 20%
• Indeterminate Lung Lesions 20%
• High-risk Lesions 20%
• Nodule Management 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Lung Lesion 100%
• Prevalence 25%